{"url_path":"/sec/inm/8-k/2026-07-22/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-22","source_url":"https://www.sec.gov/Archives/edgar/data/1728328/0001213900-26-080414-index.html","accession_number":"0001213900-26-080414","cik":"0001728328","ticker":"INM","issuer_name":"InMed Pharmaceuticals Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1728328/0001213900-26-080414-index.html","primary_entity_key":"0001728328","primary_entity_name":"InMed Pharmaceuticals Inc."},"word_count":166,"has_tables":true,"body_markdown":"**Item 9.01 Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits.\n\n \n\n**Exhibit\nNumber**\n \n**Description**\n\n10.1*\n \n[Amendment No. 1 to Securities Purchase Agreement, dated as of July 22, 2026, by and among Mentari Therapeutics, Inc. and the investors party thereto](ea029864401ex10-1.htm)\n\n99.1\n \n[Press Release, issued on July 22, 2026](ea029864401ex99-1.htm)\n\n104\n \nCover Page Interactive Data File (formatted as Inline XBRL)\n\n  \n\n*Exhibits and/or schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish\nsupplementally copies of any of the omitted exhibits and schedules upon request by the SEC; provided, however, that the registrant may\nrequest confidential treatment pursuant to Rule 24b-2 under the Exchange Act for any exhibits or schedules so furnished.\n\n \n\n2\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934,\nthe registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n**INMED PHARMACEUTICALS INC.**\n\n \n(Registrant)\n\n \n \n \n\nDate: July 22, 2026\nBy:\n/s/ Eric A. Adams                   \n\n \nName: \nEric A. Adams\n\n \nTitle:\nPresident & CEO\n\n \n\n3"}